Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

61. The effects of exercise-based interventions on health-related quality of life and physical function in patients with lung cancer receiving medical antineoplastic treatments: focusing on older patients

The effects of exercise-based interventions on health-related quality of life and physical function in patients with lung cancer receiving medical antineoplastic treatments: focusing on older patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

62. Systematic review and meta-analysis of Icotinib versus pemetrexed in treated non-small-cell lung cancer

Systematic review and meta-analysis of Icotinib versus pemetrexed in treated non-small-cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

63. Prognostic value of immunohistochemical detection of carcinoma-associated fibroblasts in non-small cell lung cancer: a systematic review and meta-analysis

Prognostic value of immunohistochemical detection of carcinoma-associated fibroblasts in non-small cell lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

64. A systematic review and network meta-analysis of bone-modifying agents for metastatic lung cancer

A systematic review and network meta-analysis of bone-modifying agents for metastatic lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

65. Prognostic value of pre-treatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis

Prognostic value of pre-treatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

66. Sex and gender difference in risk of developing lung cancer and lung cancer specific survival: a systematic review and meta-analysis

Sex and gender difference in risk of developing lung cancer and lung cancer specific survival: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

67. Residential radon and lung cancer risk by histologic subtype: a meta-analysis of case-control studies

Residential radon and lung cancer risk by histologic subtype: a meta-analysis of case-control studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

68. Relationship between microRNA expressions and the importance on its chemoresistance and susceptibility in lung cancer: a systematic review and meta-analysis protocol

Relationship between microRNA expressions and the importance on its chemoresistance and susceptibility in lung cancer: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

69. Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer

Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

70. Effectiveness of non-pharmacological interventions to manage fatigue in patients with lung cancer: a systematic review and meta-analysis

Effectiveness of non-pharmacological interventions to manage fatigue in patients with lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

71. The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II

The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2019 PROSPERO

72. Systematic review of prevalence, treatments and clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and uncommon EGFR mutations

Systematic review of prevalence, treatments and clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and uncommon EGFR mutations Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

73. The effect of diabetes mellitus on survival outcomes of patients with non-small cell lung cancer: a systematic review and meta-analysis

The effect of diabetes mellitus on survival outcomes of patients with non-small cell lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

74. Efficacy of carboplatin plus S-1 (CS) for the treatment of non-small cell lung cancer (NSCLC): a protocol for a systematic review of randomized controlled trials

Efficacy of carboplatin plus S-1 (CS) for the treatment of non-small cell lung cancer (NSCLC): a protocol for a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

75. A systematic review of Mendelian randomization studies in lung cancer

A systematic review of Mendelian randomization studies in lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

76. A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer

A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

77. A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II

A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

78. Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients: cohort study with systematic review and meta-analysis

Expression of estrogen receptor beta and overall survival in non-small cell lung cancer patients: cohort study with systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

79. Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol [Cochrane protocol]

Checkpoint inhibitors for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent: a generic protocol [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

80. Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status [Cochrane protocol]

Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO